These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 23047023

  • 21. Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.
    Luques L, Shoham S, Weinstock M.
    Exp Neurol; 2007 Aug; 206(2):209-19. PubMed ID: 17580085
    [Abstract] [Full Text] [Related]

  • 22. Preclinical pharmacology of metrifonate.
    Jann MW.
    Pharmacotherapy; 1998 Aug; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
    [Abstract] [Full Text] [Related]

  • 23. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP.
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease.
    Daiello LA, Ott BR, Festa EK, Friedman M, Miller LA, Heindel WC.
    J Clin Psychopharmacol; 2010 Jun; 30(3):245-51. PubMed ID: 20473058
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The effect of attentional dysfunction in Alzheimer's disease: theoretical and practical implications.
    Foldi NS, Lobosco JJ, Schaefer LA.
    Semin Speech Lang; 2002 May; 23(2):139-50. PubMed ID: 11951174
    [Abstract] [Full Text] [Related]

  • 29. [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences].
    Nieoullon A.
    Psychol Neuropsychiatr Vieil; 2010 Jun; 8(2):123-31. PubMed ID: 20525543
    [Abstract] [Full Text] [Related]

  • 30. Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.
    Bentley P, Driver J, Dolan RJ.
    Brain; 2008 Feb; 131(Pt 2):409-24. PubMed ID: 18077465
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update.
    Weinstock M.
    Neurodegeneration; 1995 Dec; 4(4):349-56. PubMed ID: 8846227
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cholinesterase inhibitors and beyond.
    Pepeu G, Giovannini MG.
    Curr Alzheimer Res; 2009 Apr; 6(2):86-96. PubMed ID: 19355843
    [Abstract] [Full Text] [Related]

  • 38. Cholinergic strategies in the treatment of Alzheimer's disease.
    Davidson M, Stern RG, Bierer LM, Horvath TB, Zemishlani Z, Markofsky R, Mohs RC.
    Acta Psychiatr Scand Suppl; 1991 Apr; 366():47-51. PubMed ID: 1897375
    [Abstract] [Full Text] [Related]

  • 39. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.
    Lawrence AD, Sahakian BJ.
    Neurochem Res; 1998 May; 23(5):787-94. PubMed ID: 9566619
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.